콜레라 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Cholera vaccines market size is set to record an 8.4% CAGR during 2024-2032 driven by the rising incidence of cholera and heightened awareness of its public health implications.

According to the WHO, in 2023, cholera affected over 667,000 individuals, leading to 4,000 reported fatalities. The disease remains a pressing concern in numerous developing regions, especially where sanitation and water supply are lacking. Frequent cholera outbreaks, often intensified by natural disasters and conflicts, underscore the urgent need for effective vaccination campaigns to curb the spread of the disease.

Innovations have made way for more effective, longer-lasting vaccines, bolstering protection and minimizing the frequency of doses. The introduction of new vaccine formulations, coupled with enhanced delivery methods like oral vaccines that simplify administration in resource-limited settings fuels the market expansion.

The overall industry is segmented into product, end-user, and region.

Based on product, the cholera vaccines market size from the Vaxchora segment is expected to generate notable revenue by 2032. This is due to its role as the first and only FDA-approved oral cholera vaccine specifically designed for travelers to endemic regions. This unique oral formulation offers a convenient and effective means of protection against cholera, addressing a significant need for pre-travel immunization.

In terms of end-user, the cholera vaccines market value from the private segment is projected to observe a robust CAGR during 2024 - 2032 owing to the increasing awareness and demand for preventive healthcare solutions among individuals and organizations. Private healthcare providers and institutions are increasingly offering cholera vaccination services as part of their preventive care and travel health programs.

Asia Pacific cholera vaccines industry size will grow substantially between 2024 and 2032 attributed to the high incidence of cholera outbreaks and ongoing public health challenges related to sanitation and water quality. Rapid urbanization, population growth, and environmental factors contribute to the spread of cholera, further necessitating robust vaccination efforts. The increased government and NGO initiatives focused on improving health infrastructure and disease prevention in vulnerable communities are boosting vaccine uptake, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculations
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of cholera outbreaks.
    • 3.2.1.2 Growing governments support
    • 3.2.1.3 Expanding research funding and activities
    • 3.2.1.4 Growing travel to endemic regions
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of access to adequate treatment
    • 3.2.2.2 Cold chain requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Dukoral
• 5.3 Vaxchora
• 5.4 Euvichol/Euvichol-Plus
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Public
• 6.3 Private

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 UK
  • 7.3.2 France
  • 7.3.3 Spain
  • 7.3.4 Netherlands
  • 7.3.5 Belgium
  • 7.3.6 Croatia
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 India
  • 7.4.2 Bangladesh
  • 7.4.3 Pakistan
  • 7.4.4 Philippines
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Columbia
  • 7.5.2 Peru
  • 7.5.3 Chile
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Syria
  • 7.6.2 Uganda
  • 7.6.3 Yemen
  • 7.6.4 Kenya
  • 7.6.5 Zimbabwe
  • 7.6.6 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Bavarian Nordic A/S
• 8.2 Bharat Biotech
• 8.3 Biological E
• 8.4 EuBiologics Co. Ltd.
• 8.5 Hilleman Laboratories
• 8.6 Incepta Pharmaceuticals Ltd.
• 8.7 Shantha Biotechnics (Sanofi)
• 8.8 Vabiotech
• 8.9 Valneva Sweden AB